Talvey Plus Darzalex Faspro Data Demonstrate the Strength of a Bispecific Combination in Earlier-Line Relapsed or Refractory Multiple Myeloma
June 13, 2026
June 13, 2026
RARITAN, New Jersey, June 13 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
New TALVEY(R) (talquetamab-tgvs) plus DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
Key takeaways
- TALVEY(R) plus DARZALEX FASPRO(R) with or without pomalidomide showed progression-free survival of up to 81% an . . .
* * *
New TALVEY(R) (talquetamab-tgvs) plus DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
Key takeaways
- TALVEY(R) plus DARZALEX FASPRO(R) with or without pomalidomide showed progression-free survival of up to 81% an . . .